Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XTNTthis companyXtant Medical Holdings, Inc.	$0.28	19.6×	2.15×	0.82×	7.62×	-2076.9%	62.9%	5.4%	3.7%	9.8%	6.5%	9.3%	0.56×	0.73×	1.98×	2.65×	0.0%	3	-2.47	2	C
APYXApyx Medical Corporation	$3.00	-12.96×	10.15×	2.79×	-33.8×	-284.7%	36.0%	-12.2%	-21.2%	-77.1%	-11.6%	-6.2%	2.71×	-1.66×	-1.15×	5×	0.0%	3	0.84	1	D+
ESLAEstrella Immunopharma, Inc.	$0.50	-4.46×	-5.54×	0×	-4.29×	-94.4%	0.0%	0.0%	0.0%	126.0%	126.0%	-3.1%	0×	0.11×	0×	0.12×	0.0%	2	-52.49	2	C
EXOZeXoZymes, Inc.	$4.21	-10×	26.89×	0×	-9.98×	-96.8%	0.0%	0.0%	0.0%	-269.6%	-203.1%	-7.3%	0.37×	0.2×	0×	2.51×	0.0%	1	-2.59	1	C-
LUCDLucid Diagnostics Inc.	$0.42	-1.58×	10.16×	23.61×	-1.79×	-873.4%	-60.3%	-1054.8%	-1232.7%	-530.4%	-135.1%	-41.8%	2.36×	0.16×	-2,256.36×	1.31×	0.0%	3	-13.58	2	C
NSPRInspireMD, Inc.	$0.65	-2.34×	2.37×	14.56×	-2.59×	-939.0%	29.5%	-547.0%	-543.3%	-88.4%	-82.2%	-28.1%	0.06×	0.12×	0×	5.74×	0.0%	2	-11.16	2	C+
Peer median	—	-4.46×	10.15×	2.79×	-4.29×	-284.7%	0.0%	-12.2%	-21.2%	-88.4%	-82.2%	-7.3%	0.37×	0.12×	0×	2.51×	0.0%	2	-11.16	2	—